In-Depth Examination Of 4 Analyst Recommendations For GoodRx Holdings

4 analysts have shared their evaluations of GoodRx Holdings GDRX during the recent three months, expressing a mix of bullish and bearish perspectives.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $6.75, a high estimate of $8.00, and a low estimate of $4.50. Surpassing the previous average price target of $6.17, the current average has increased by 9.4%.

Analyzing Analyst Ratings: A Detailed Breakdown

The standing of GoodRx Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to GoodRx Holdings. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of GoodRx Holdings compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for GoodRx Holdings's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

For valuable insights into GoodRx Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on GoodRx Holdings analyst ratings.

All You Need to Know About GoodRx Holdings

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers other healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Understanding the Numbers: GoodRx Holdings's Finances

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Challenges: GoodRx Holdings's revenue growth over 3 months faced difficulties. As of 30 September, 2023, the company experienced a decline of approximately -3.93%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: GoodRx Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -21.39% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -4.33%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): GoodRx Holdings's ROA excels beyond industry benchmarks, reaching -2.26%. This signifies efficient management of assets and strong financial health.

Debt Management: GoodRx Holdings's debt-to-equity ratio is below the industry average at 0.81, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: What Are They?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.